Pharmacotherapy and surgical treatment of adult granulosa cell ovarian tumors: analysis of own and literature data


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Granulosa cell ovarian tumors (GCOTs) are rare non-epithelial neoplasms, and according to some data, their incidence rate is about 3-5% of all malignant ovarian tumors. However, according to a number of authors, the data on the incidence rate of GCOTs do not sufficiently reflect the true situation, since the majority of cancer registries in the world do not take into account these tumors. Objective. Determination of the role of pharmacotherapy and surgical methods in the treatment of patients with adult granulosa cell ovarian tumors (AGCOTs). Methods. The study included data on 93 patients with AGCOTs who were treated and followed up at the N.N. Petrov NRMCO from 1980 to 2017. The median follow-up period was 118 months (from 6 to 423 months). Results. 74 (79.6%) patients were diagnosed with stage I disease. The IA stage was identified in 51 (54.8%) patients, IB - in 6 (6.5%), and IC - in 17 (18.3%) patients. 19 (20.4%) patients were diagnosed with stage II - IV of the disease. The stage of the disease significantly influenced the 5-year survival rates (p<0.05). It was 43.8% in patients with III - IV stage. All patients with stage III - IV had a relapse of the disease. All patients underwent surgical treatment. Adjuvant chemotherapy (AHT) in stage I was administered for 51 patients, in II - IV stages of the disease - for all patients. Relapse of the disease occurred in 34 (36.6%) patients. The average time to the first recurrence was 55 months (from 3 to 312). Among 74 patients with stage I disease, relapses were observed in 18 (24.3%). In stage II - IV, AGCOT recurrences were registered in all cases. Conclusion. Tere were no significant differences in the overall and relapse-free survival of patients with AGCOTs, depending on the options of surgical treatment and pharmacotherapy. The results obtained and literature data indicate a favorable course of the disease in the IA stage and in the absence of adverse risk factors, which allows to perform the operations that preserve fertility in patients of reproductive age. Additional multicentre randomized studies to clarify the effectiveness of various surgical and drug treatment options for patients with AGCOTs are required.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Elena Bakhidze

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

Email: bakhidze@yandex.ru
MD, Leading researcher at the Department of Onogynecology; Associate Professor at the Department of Obstetrics and Gynecology 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation

V. Belyaeva

St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncological)

St. Petersburg, Russia

A. Domansky

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

N. Mikaya

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov

St. Petersburg, Russia

Әдебиет тізімі

  1. Gatta, G., Van DerZwan J.M., Casali P.G., et al. Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008.
  2. Bryk S., Pukkala E., Martinsen J.I., et al. Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953-2012: a longitudinal cohort study. BJOG. 2017;124(1):143-49. doi: 10.1111/1471-0528.13949.
  3. Ray-Coquard I., Morice P., Lorusso D., et al. Nonepithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):iv1-iv18. doi: 10.1093/annonc/mdy001.
  4. Schultz K.A., Harris A.K., Schneider D.T., et al. Ovarian Sex Cord-Stromal Tumors. J Oncol Pract. 2016;12(10):940-46. Doi:10.1200/ jop.2016.016261.
  5. Young R. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Modern Pathol. 2005;18:81-91. doi: 10.1007/978-3-642-38971-9_7.
  6. Young R. Ovarian sex cord-stromal tumours and their mimics. Pathology. 2018;50(Issue 1):5-15. doi: 10.1016/j.pathol.2017.09.007.
  7. Dey P. Pathology of Ovary: Sex Cord Tumours. In: Color Atlas of Female Genital Tract Pathology. Springer, 2019. doi: 10.1007/978-981-13-1029-4_8.
  8. Тюляндин С.А., Кержковская Н.С., Стрельцова О.Н. Герминогенные и гранулезоклеточные опухоли яичников. Практическая онкология. 2009;10(2):11-116.
  9. Badawi I.A., Brasher P.M., Ghatage P., et al. Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2002;12:119-23.
  10. Gershenson D.M., Copeland L.J., Kavanagh J.J., et al. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol. 1987;70:765-69.
  11. Uygun K., Aydiner A., Saip P., et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary Gynecol Oncol. 2003;88:400-3.
  12. Homesley H.D., Bundy B.N., Hurteau J.A., Roth L.M. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;72:131-37.
  13. Schumer S.T, Cannistra S.A. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180-89.
  14. Colombo N., Parma G., Zanagnolo V., Insinga A. Management of Ovarian Stromal Cell Tumors. J Clin Oncol. 2007;25:2944-51. doi: 10.1200/JCO.2007.11.1005.
  15. Colombo N, Peiretti M., Garbi A., et al. Nonepithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment. Ann Oncol. 2012;23(7):vii20-vii26. doi: 10.1093/annonc/mds223.
  16. Prat J. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum. European journal of obstetrics, gynecology, and reproductive biology. 2015;26(2). doi: 10.1016/j.ejogrb.2015.03.010.
  17. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Ed. by FA. Tavassoli, P Devilee. IARC press, 2003. 432 p. URL: https://doi.org/10.1186/bcr788.
  18. Fritz A., et al. International Classification of Diseases for Oncology (ICD-O). 3rd ed. World Health Organization: Geneva, 2000.
  19. Park J.Y, Jin K.L., Kim D.Y., et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2012;125:80-6. doi: 10.1080/01443615.2017.1332579.
  20. Ayhan A., Salman M.C., Velipasaoglu M., et al. Prognostic factors in adult granulose cell tumors of the ovary: a retrospective analysis of 80 cases. J Gynecol Oncol. 2009;20:158-63. Doi: 10.3802/ jgo.2009.20.3.158.
  21. Ranganath R., Sridevi V, Shurkey S.S., Shanta V Clinical and pathologic prognostic factors in adult granulosa cell tumors of the ovary. Int J Gynecol Cancer. 2008;18:929-33. doi: 10.1111/j.1525-1438.2007.01154.x.
  22. Бахидзе Е.В. Современные подходы к диагностике, лечению и прогнозу гранулезоклеточных опухолей яичников (анализ литературных данных и собственных исследований). Фарматека. 2013;17:22-25.
  23. Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H. HO Classifi cation of Tumours of Female Reproductive Organs. IARC: Lyon, 2014.
  24. Chan J.K., Zhang M., Kaleb V., et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-- a multivariate analysis. Gynecol Oncol. 2005;96(1):204-9. doi: 10.1016/j.ygyno.2004.09.019.
  25. Nosov V, Silva I., Tavassoli F., et al. Predictors of recurrence of ovarian granulosa cell tumors. Int J Gynecol Cancer. 2009;19(4):628-33. doi: 10.1111/IGC.0b013e3181a48a6f.
  26. Thomakos N., Biliatis I., Koutroumpa I., et al. Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary Arch Gynecol Obstet. 2016;294(5):1031-36. doi: 10.1007/s00404-016-4135-5.
  27. Babarovi E., Franin I., Klari M., et al. Adult Granulosa Cell Tumors of the Ovary: A Retrospective Study of 36 FIGO Stage I Cases with Emphasis on Prognostic Pathohistological Features. Anal Cell Pathol (Amst). 2018;2018:9148124. doi: 10.1155/2018/9148124.
  28. Auranen A., Sundström J., Ijäs J., Grenman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer. 2007;17(5):1011-18.
  29. Bryk S., Färkkilä A., Bützow R. Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2016;143(3):571-77. doi: 10.1016/j.ygyno.2016.10.002.
  30. Dridi M., Chraiet N., Batti R., et al. Granulosa Cell Tumor of the Ovary: A Retrospective Study of 31 Cases and a Review of the Literature. Int J Surg Oncol. 2018;4547892. doi: 10.1155/2018/4547892.
  31. Mangili G., Ottolina J., Gadducci A., et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013;109(1 ):29-34. doi: 10.1038/bjc.2013.241.
  32. Karalok A., Turan T., Ureyen I., et al. Prognostic factors in adult Granulosa cell tumor: a long follow-up at a single center. Int J Gynecol Cancer. 2016;26(4):619-25. doi: 10.1097/IGC.0000000000000659.
  33. Lee I.H., Choi C.H., Hong D.G., et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol. 2011;22(3):188-195. doi: 10.3802/jgo.2011.22.3.188.
  34. Abdul Munem A., Bahrani B., Mehdi I., et al. Aromatase inhibitors-- a viable option for recurrent granulosa cell tumour of ovary: overview and case report. J Pak Med Assoc. 2012;62(5):505-7.
  35. Meisel J.L., Hyman D.M., Jotwani A., et al. The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecol Oncol. 2015;136(3):505-11. doi: 10.1016/j.ygyno.2014.12.026.
  36. Pautier P., Gutierrez-Bonnaire M., Rey A., et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2018;3:446-52.
  37. Бейшембаев А.М., Хайленко В.А., Любимова Н.В. и др. Диагностика и лечение рецидивов гранулезоклеточных опухолей яичников. Опухоли женской репродуктивной системы. 2009;3-4:112-16. doi: 10.17650/1994-4098-2009-03-4-112-116. doi: 10.17650/1994-40982009-0-3-4-112-116.
  38. Mangili G., Ottolina J., Cormio G., et al. Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study. Gynecol Oncol. 2016;143(2):276-80. doi: 10.1016/j.ygyno.2016.08.316.
  39. Wang D., Xiang Y., Wu M., et al. Is adjuvant chemotherapy beneficial for patients with FIGO stage IC adult granulosa cell tumor of the ovary? J Ovar Res. 2018;11:25. doi: 10.1186/s13048-018-0396-x.
  40. Briasoulis E., Karavasilis V., Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary Ann Oncol. 1997;11: 811-12.
  41. Kauppila A, Bangah M., Burger H., Martikainen H. GnRH agonist analog therapy in advanced/ recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol. 1992;6:271-74.
  42. Hardy R.D., Bell J.G., Nicely C.J., Reid G.C. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005;96(3):865-69.
  43. Fishman A., Kudelka A.P., Tresukosol D., et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med. 1996;41:393-96.
  44. Korach J., Perri T., Beiner M., et al. Promising effect of aromatase inhibitors on recurrent granulosa cell tumours. Int J Gynecol Cancer. 2009;19:830-33.
  45. Freeman S.A., Modesitt S.C. Anastrozole therapy in recurrent ovarian adult granulosa cell tumours: a report of 2 cases. Gynecol Oncol. 2006;103: 755-58.
  46. Hilli M.M., Long H.J., Podratz K.C., Bakkum-Gamez J.N. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012;38:340-44.
  47. Rico C., Lagué M.N., Lefévre P., et al. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. Carcinogenesis. 2012;11:2283-92.
  48. Raspagliesi F., Martinelli F., Grijuela B., Guadalupi V. Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: case report. Obstet Gynaecol Res. 2011;37(12):1864-67. doi: 10.1111/j.1447-0756.2011.01649.x.
  49. Jamieson S., Fuller P.J. Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. Int J Gynecol Cancer. 2015;25(7):1224-31. doi: 10.1097/IGC.0000000000000479.
  50. Poddubskaya E.V., Baranova M.P., Allina D.O. et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol Case Stud. 2019;5(2):pii:a003434. doi: 10.1101/mcs.a003434.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>